Shanghai Kaibao Pharmaceutical CO.,Ltd (SZSE: 300039)
Health Care · Pharmaceuticals · CN
CN¥5.54
-8.13% today · -19.0% 1Y
Shanghai Kaibao Pharmaceutical CO.,Ltd (SZSE: 300039) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $862.02M and employs 1,197 people.
Over the last twelve months the share price has lost 19.0%, trading between 4.02 and 6.90.
Tweenvest scores Shanghai Kaibao Pharmaceutical CO.,Ltd across four factors: quality 74/100, value 40/100, growth 21/100, dividend 28/100. Its strongest factor is quality.
300039 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $862.02M
- Revenue (TTM)
- $150.10M
- P/E
- 22.37
- EPS
- 0.25
- Dividend yield
- 3.61%
- Beta (5Y)
- 0.17
- 52-week high
- CN¥6.90
- 52-week low
- CN¥4.02
- Avg volume (3M)
- —
- Shares outstanding
- 1.05B
- Employees
- 1,197
- Next earnings
- —
About Shanghai Kaibao Pharmaceutical CO.,Ltd
Shanghai Kaibao Pharmaceutical CO.,Ltd specializes in the research, development, manufacturing, and sale of modern Traditional Chinese Medicines, primarily operating within China. Its diverse product lineup features several key pharmaceutical solutions. These include: Tanreqing injection, which is extensively utilized for addressing conditions like pneumonia, acute and chronic bronchitis, and upper respiratory tract infections. Tanreqing capsules, formulated to reduce internal heat, detoxify the system, and clear phlegm. Tiopronin for injection, designed to enhance liver function for various acute and chronic hepatitis patients. Tiopronin enteric-coated tablets, prescribed as a supplementary therapy for managing chronic hepatitis. Xiongdan dropping pills, known for their efficacy in alleviating heat, calming the liver, and promoting improved vision. Established in 2000, the company's operations are based in Shanghai, China.
- ISIN
- CNE100000JZ3
- Founded
- 2000
- Listed since
- Jan 8, 2010
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,217.60 | -1.30% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $271.62 | -0.56% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $154.85 | -1.02% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.20 | -1.50% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.46 | -1.84% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.96% |
Figures last refreshed Aug 18, 2026.